JPHC CE: Pharmacological Management of Spasticity in Children With Cerebral Palsy
1.5 NAPNAP contact hour of which contain 1.5 pharmacology content and 0.25 controlled substance. This continuing education activity is offered free to NAPNAP Members. For non- members, this continuing education activity rate is $10. Cerebral palsy (CP), a nonprogressive disease of the central nervous system, is the most common motor disability in childhood. Patients with CP often have a multitude of associated comorbidities, including impact on muscle tone. There are four main types of CP, with spastic as the most commonly diagnosed. The American Academy of Neurology and Child Neurology Society released a practice parameter regarding the pharmacological management of CP-related spasticity in 2010. This continuing education review evaluates the available safety and efficacy evidence for oral and parenteral pharmacological agents used to reduce spasticity in children with CP and provides a reference for practitioners managing these patients. J Pediatr Health Care. (2020) 34, 409−509.
Important: You must be logged in to use your NAPNAP Member ID# and Password to be recognized as a Member of NAPNAP. If you are a current member of NAPNAP, and you are being asked to purchase this activity, please contact the NAPNAP National Office at (877) 662-7627 to request assistance prior to entering any information.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: email@example.com
Copyright © 2020 by the National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved.
This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the post test will be awarded 1.5 NAPNAP contact hours of which 1.5 contain pharmacology content and 0.25 is related to controlled substance.
Pediatric-focused advanced practice registered nurses
- Recognize available medications used to manage cerebral palsy−associated spasticity.
- Evaluate the pharmacology of and current efficacy and safety data on oral and parenteral medications used to manage spasticity in children with cerebral palsy.
- Describe practical and patient-specific considerations when choosing between medications used to manage spasticity in children with cerebral palsy.
Mary Reilly, PharmD Post-Graduate Year 1 Pharmacy Resident, University of Kentucky, Lexington, KY.
Kayley Liuzzo, Pediatric Clinical Pharmacist, Department of Pharmacy, Children’s Hospital Colorado, Aurora, CO.
Allison B. Blackmer, Associate Professor of Pharmacy; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and Clinical Pharmacist Specialist, Special Care Clinic, Children’s Hospital Colorado, Aurora, CO.
Conflicts of interest: None to report.
Correspondence: Allison B. Blackmer, PharmD, FCCP, BCPS, BCPPS
Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.
12850 East Montview Blvd., V20-1208, Mail Stop C238, Aurora,CO 80045
- 1.50 Contact hours